Pluristem and CHA Move Forward on Strategic Partnership Agreement; Conclude Mutual Investment of $10.4 Million

Pluristem and CHA Move Forward on Strategic Partnership Agreement; Conclude
Mutual Investment of $10.4 Million

Key Points

  *Pluristem issues shares to CHA at a price per share of $4.16
  *Development and Commercialization of PLX-PAD cells for the Treatment of
    Peripheral Artery Disease in South Korea

HAIFA, Israel, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR) today announced that pursuant to the previously
announced exclusive out-license and strategic partnership agreement between
Pluristem Ltd. and South Korea-based CHA Bio&Diostech (Kosdaq:CHA), the
details of which were announced on June 26, 2013, Pluristem and CHA entered
into investment agreements pursuant to which Pluristem has issued to CHA
2,500,000 shares of its common stock in consideration for the issuance to
Pluristem of 1,011,504 shares of CHA. This reflects a total consideration of
$10.4 million, at a price of $4.16 per Pluristem common share, a premium of
26% over the closing price on December 16, 2013. The shares are subject to a
lock up period of one year.

The previously announced agreement with CHA encompasses the use of Pluristem's
PLX-PAD cells in the treatment of two subsets of Peripheral Artery Disease
(PAD) in South Korea: Intermittent Claudication (IC) and Critical Limb
Ischemia (CLI).

Zami Aberman, Pluristem's Chairman and CEO stated, "We are excited to finalize
and move forward with this strategic agreement with CHA Bio. We believe that
initiating clinical trials with CHA Bio for indications in the area of
peripheral vascular disease opens significant opportunities for Pluristem in
South Korea's dynamic regenerative medicine industry. We also look forward to
potentially expanding the use of our PLX cells for other indications with our
partner, CHA Bio."

The first clinical study to be performed as part of the agreement will be a
Phase II trial in IC which will run in parallel to the Phase II trial being
conducted in the USA, Germany and Israel. As previously announced, this study
was approved in November 2013 by South Korea's Ministry of Food and Drug
Safety (MFDS). Pursuant to the previously announced agreement with CHA, upon
the first regulatory approval for a PLX product in South Korea, Pluristem and
CHA Bio will establish a joint venture (JV) co-owned by the parties. The
purpose of the JV will be to commercialize PLX cell products in South Korea.
Additionally, Pluristem will be able to use the data generated by CHA Bio to
pursue the development of PLX product candidates outside of South Korea.

About CHA Bio&Diostech

CHA Bio&Diostech Co., Ltd. is a leading biopharmaceutical company
headquartered in South Korea; its R&D focuses on stem cells, cell
therapeutics, medical device, and new drug development. The company is a
member of CHA Health Systems Group, which is composed of a medical university,
medical centers and hospitals located in the US and Korea with in excess of
two thousand beds under care, stem cell research centers, personal &
preventive medicine, and bio venture divisions. CHA Bio&Diostech has multiple
stem cell R&D pipelines in therapeutic areas including Stargardt's disease,
age-related macular disease, Parkinson's disease, Alzheimer disease, Cerebral
Palsy and glioblastoma in mid-to late-stages of development. With its
extensive experience and research infrastructure, CHA Bio&Diostech has built
up multiple strategic relations with major research institutions in the fields
of stem cell research and infertility. For more information visit
www.chabio.com, the content of which is not part of this press release.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss the, we are
using forward-looking statements. For example, we are using forward looking
statement when we discuss our belief that initiating clinical trials with CHA
Bio for indications in the area of peripheral vascular disease opens
significant opportunities for us in South Korea's medicine industry and that
we look forward to potentially expanding the use of our PLX cells for other
indications with CHA Bio, or when we discuss the Phase II trial in IC to be
conducted as part of our agreement with CHA. These forward-looking statements
and their implications are based on the current expectations of the management
of Pluristem only, and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in
the forward-looking statements. The following factors, among others, could
cause actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements; we
may encounter delays or obstacles in launching and/or successfully completing
our clinical trials; our products may not be approved by regulatory agencies,
our technology may not be validated as we progress further and our methods may
not be accepted by the scientific community; we may be unable to retain or
attract key employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our process; our
products may wind up being more expensive than we anticipate; results in the
laboratory may not translate to equally good results in real surgical
settings; results of preclinical studies may not correlate with the results of
human clinical trials; our patents may not be sufficient; our products may
harm recipients; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; loss of market share
and pressure on pricing resulting from competition, which could cause the
actual results or performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required
by law, Pluristem undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. For a
more detailed description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with the
Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:

         Karine Kleinhaus, MD, MPH
         Director of Investor Relations
         1-914-512-4109
         karinek@pluristem.com

         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.